Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
RecombinantRabMAb

Recombinant Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)

Submit a review Submit a question References (7)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
  • Western blot - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
  • Immunocytochemistry - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
  • Immunocytochemistry - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
  • Immunocytochemistry - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
  • Flow Cytometry (Intracellular) - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
  • OI-RD Scanning - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
  • Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [YR85] to Progesterone Receptor - BSA and Azide free
  • Suitable for: ICC, IHC-P, IP, WB, Flow Cyt (Intra)
  • Reacts with: Human

Conjugates logo Related conjugates and formulations

Unconjugated

Overview

  • Product name

    Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free
    See all Progesterone Receptor primary antibodies

  • Description

    Rabbit monoclonal [YR85] to Progesterone Receptor - BSA and Azide free

  • Host species

    Rabbit

  • Tested applications

    Suitable for: ICC, IHC-P, IP, WB, Flow Cyt (Intra)more details

  • Species reactivity

    Reacts with: Human

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • Human breast carcinoma, T47D cell lysate. This antibody gave a positive result when used in the following formaldehyde fixed cell lines: DU145.

  • General notes

    ab206926 is the carrier-free version of ab32085.

    Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.

    This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

    Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

    This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

Properties

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab206926 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC
Use at an assay dependent concentration.
IHC-P
Use at an assay dependent concentration. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
IP
Use at an assay dependent concentration.
WB
Use at an assay dependent concentration. Detects a band of approximately 135 kDa (predicted molecular weight: 98 kDa).

Please check the parent abID, ab32085, for more information on dilutions.
Flow Cyt (Intra)
Use at an assay dependent concentration.
Notes
ICC
Use at an assay dependent concentration.
IHC-P
Use at an assay dependent concentration. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
IP
Use at an assay dependent concentration.
WB
Use at an assay dependent concentration. Detects a band of approximately 135 kDa (predicted molecular weight: 98 kDa).

Please check the parent abID, ab32085, for more information on dilutions.
Flow Cyt (Intra)
Use at an assay dependent concentration.

Target

  • Function

    The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.
    Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.
    Isoform 4: Increases mitochondrial membrane potential and cellular respiration upon stimulation by progesterone.

  • Sequence similarities

    Belongs to the nuclear hormone receptor family. NR3 subfamily.
    Contains 1 nuclear receptor DNA-binding domain.

  • Domain

    Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain.

  • Post-translational
    modifications

    Phosphorylated on multiple serine sites. Several of these sites are hormone-dependent. Phosphorylation on Ser-294 occurs preferentially on isoform B, is highly hormone-dependent and modulates ubiquitination and sumoylation on Lys-388. Phosphorylation on Ser-102 and Ser-345 also requires induction by hormone. Basal phosphorylation on Ser-81, Ser-162, Ser-190 and Ser-400 is increased in response to progesterone and can be phosphorylated in vitro by the CDK2-A1 complex. Increased levels of phosphorylation on Ser-400 also in the presence of EGF, heregulin, IGF, PMA and FBS. Phosphorylation at this site by CDK2 is ligand-independent, and increases nuclear translocation and transcriptional activity. Phosphorylation at Ser-162 and Ser-294, but not at Ser-190, is impaired during the G(2)/M phase of the cell cycle. Phosphorylation on Ser-345 by ERK1/2 MAPK is required for interaction with SP1.
    Sumoylation is hormone-dependent and represses transcriptional activity. Sumoylation on all three sites is enhanced by PIAS3. Desumoylated by SENP1. Sumoylation on Lys-388, the main site of sumoylation, is repressed by ubiquitination on the same site, and modulated by phosphorylation at Ser-294.
    Ubiquitination is hormone-dependent and represses sumoylation on the same site. Promoted by MAPK-mediated phosphorylation on Ser-294.
    Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.

  • Cellular localization

    Nucleus. Cytoplasm. Nucleoplasmic shuttling is both homone- and cell cycle-dependent. On hormone stimulation, retained in the cytoplasm in the G(1) and G(2)/M phases; Mitochondrion outer membrane and Nucleus. Cytoplasm. Mainly nuclear.
  • Information by UniProt

  • Database links

    • Alternative names

      • NR3C3 antibody
      • Nuclear receptor subfamily 3 group C member 3 antibody
      • PGR antibody
      • PR antibody
      • PRA antibody
      • PRB antibody
      • PRGR_HUMAN antibody
      • Progesterone receptor antibody
      • Progestin receptor form A antibody
      • Progestin receptor form B antibody
      see all

    Images

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
      Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)

      Immunohistochemical analysis of progesterone receptor expression in paraffin embedded human breast carcinoma, using 1/100 ab32085.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32085).

      Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

    • Western blot - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
      Western blot - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
      Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926) + Human breast cancer lysate at 10 µg

      Secondary
      Goat Anti-Rabbit IgG H&L (HRP) (ab97051)

      Predicted band size: 98 kDa
      Observed band size: 135 kDa why is the actual band size different from the predicted?


      Exposure time: 3 minutes


      Blocking buffer and concentration: 5% NFDM/TBST

      Diluting buffer and concentration: 5% NFDM/TBST

    • Immunocytochemistry - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
      Immunocytochemistry - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)

      Clone YR85 (ab206926) has been successfully conjugated by Abcam. This image was generated using Anti-Progesterone Receptor antibody [YR85] (Alexa Fluor® 488). Please refer to ab199224 for protocol details.

      ab199224 staining Progesterone Receptor in MCF7 cells. The cells were fixed with 4% formaldehyde (10 min), permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated overnight at +4°C with ab199224 at a 1/100 dilution (shown in green) and ab195889, Mouse monoclonal to alpha Tubulin (Alexa Fluor® 594), at a 1/250 dilution (shown in red). Nuclear DNA was labelled with DAPI (shown in blue).

      Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).

      This product also gave a positive signal under the same testing conditions in MCF7 cells fixed with 100% methanol (5 min).

    • Immunocytochemistry - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
      Immunocytochemistry - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)

      Clone YR85 (ab206926) has been successfully conjugated by Abcam. This image was generated using Anti-Progesterone Receptor antibody [YR85] (Alexa Fluor® 647). Please refer to ab199455 for protocol details.

      ab199455 staining Progesterone Receptor in MCF7 cells. The cells were fixed with 4% formaldehyde (10 min), permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated overnight at +4°C with ab199455 at a 1/100 dilution (shown in red) and ab195887, Mouse monoclonal to alpha Tubulin (Alexa Fluor® 488), at a 1/250 dilution (shown in green). Nuclear DNA was labelled with DAPI (shown in blue).

      Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).

      This product also gave a positive signal under the same testing conditions in MCF7 cells fixed with 100% methanol (5 min).

    • Immunocytochemistry - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
      Immunocytochemistry - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)

      ICC/IF image of ab32085 stained DU145 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab32085 at 5µg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- rabbit (ab96899) IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32085).

    • Flow Cytometry (Intracellular) - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
      Flow Cytometry (Intracellular) - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)

      Intracellular Flow Cytometry analysis of T47D (human mammary gland ductal carcinoma) cells labeling Progesterone Receptor with purified ab32085 at 1/1100 dilution (1ug/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluorr® 488) (ab150077) (1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black) (ab172730) was used as the isotype control, Cell without incubation with primary antibody and secondary antibody (Blue) were used as the unlabeled control. 

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32085). 

       

       

    • OI-RD Scanning - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
      OI-RD Scanning - Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
      Equilibrium disassociation constant (KD)
      Learn more about KD

      Click here to learn more about KD

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32085).

    • Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)
      Anti-Progesterone Receptor antibody [YR85] - BSA and Azide free (ab206926)

    References (7)

    Publishing research using ab206926? Please let us know so that we can cite the reference in this datasheet.

    ab206926 has been referenced in 7 publications.

    • Argenta PA  et al. Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer. Gynecol Oncol N/A:N/A (2013). ICC/IF ; Human . PubMed: 23911795
    • Ariazi EA  et al. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A 108:18879-86 (2011). WB ; Human . PubMed: 22011582
    • Tieszen CR  et al. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer 11:207 (2011). WB . PubMed: 21619605
    • Hennessy BT  et al. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics 6:129-51 (2010). Dot blot ; Human . PubMed: 21691416
    • Hennessy BT  et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69:4116-24 (2009). PubMed: 19435916
    • Kim WY  et al. A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prev Res (Phila) 1:577-87 (2008). PubMed: 19139008
    • Yin P  et al. Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. J Clin Endocrinol Metab 92:4459-66 (2007). PubMed: 17785366

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab206926.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com